HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose ...
(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) "This approval is an important advancement for women with metastatic breast cancer, where the ...
Dr Reddy's Laboratories Ltd. announced the launch of the US Food and Drug Administration (FDA) approved fulvestrant injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe, a therapeutic equivalent ...
have not previously been treated with any hormonal therapy. In the FALCON study, eligible patients will be randomised 1:1 to receive either fulvestrant (500 mg/day intramuscular injection) on days 0, ...
Adding Truqap to Faslodex improved outcomes in patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer. Patients with HR-positive, HER2-negative locally advanced or ...
The application for capivasertib plus Faslodex in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer has also been granted priority review, meaning that the FDA has ...
We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor–positive metastatic breast cancer who had been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results